T Relapse After Non - T - cell - Depleted Allogeneic Bone Marrow ' ransplantation for Chronic Myelogenous Leukemia : Early Transplantation , Use of an Unrelated Donor , and Chronic Graft - Versus - Host Disease Are Protective

We analyzed the incidence of posttransplant chronic myelogenous leukemia (CW) relapse in 283 consecutive related-&nor (n = 177) and unretated-donor (n = 106) allogeneic transplant reoipients. Twenty-two of 165 related-donor recipients with stable or advanced disease at the time of transplant had hematologic relapse of CML following transplant (5-year Kaptan-Meier estimate of relapse, 2090; 95% confidence interval [CI], 11 t o 30%). One of 12 patients transp lan td in second stable phase following blast crisis also relapsed. Fifteen related-donor transplant recipients relapsed within 5 years of transplant; however, seven relapsed betweon 5 and 9 years after transplant. Factors independently associated with an increased risk of posttransplant relapse for related-donor recipients included prolonged interval between diagnosis and transplant (relative risk, [RR], 3.81; P = .Om) and bone marrow basophilia (RR, 5.62; P = .01). Related-donor recipients with posttransplant chronic graft-versus-host disease (CGVHD) had a decreased risk of